Healthcare -
Medical - Instruments & Supplies - NYSE - US
$ 213.0
3.82 %
$ 31.3 B
Market Cap
25.15
P/E
1. INTRINSIC VALUE
Balance Sheet
ResMed Inc.
| Current Assets | 2.36 B |
| Cash & Short-Term Investments | 238 M |
| Receivables | 837 M |
| Other Current Assets | 1.28 B |
| Non-Current Assets | 4.51 B |
| Long-Term Investments | 170 M |
| PP&E | 699 M |
| Other Non-Current Assets | 3.65 B |
| Current Liabilities | 911 M |
| Accounts Payable | 238 M |
| Short-Term Debt | 60.5 M |
| Other Current Liabilities | 612 M |
| Non-Current Liabilities | 1.1 B |
| Long-Term Debt | 839 M |
| Other Non-Current Liabilities | 259 M |
EFFICIENCY
Earnings Waterfall
ResMed Inc.
| Revenue | 4.69 B |
| Cost Of Revenue | 2.03 B |
| Gross Profit | 2.66 B |
| Operating Expenses | 1.34 B |
| Operating Income | 1.32 B |
| Other Expenses | 299 M |
| Net Income | 1.02 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
ResMed Inc.
| Net Income | 1.02 B |
| Depreciation & Amortization | 216 M |
| Capital Expenditures | -115 M |
| Stock-Based Compensation | 80.2 M |
| Change in Working Capital | 44.8 M |
| Others | -88.3 M |
| Free Cash Flow | 1.29 B |
Wall Street Analysts Price Targets
ResMed Inc.
Wall Street analysts predict an average 1-year price target for RMD of $239 , with forecasts ranging from
a
low of
$180 to a high of $280 .
RMD Lowest Price Target
Wall Street Target
180 USD
-15.49%
RMD Average Price Target
Wall Street Target
239 USD
12.21%
RMD Highest Price Target
Wall Street Target
280 USD
31.46%
4. DIVIDEND
ANALYSIS
0.23%
DIVIDEND YIELD
0.53 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
ResMed Inc.
Sold
0-3 MONTHS
10.1 M USD 5
3-6 MONTHS
8.04 M USD 6
6-9 MONTHS
26.9 M USD 6
9-12 MONTHS
12.4 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
RMD Stock Benefits From the Launch of NightOwl Across US
Resmed launches NightOwl, an FDA-cleared home sleep apnea test, in the United States to diagnose OSA at home.
zacks.com
- 2 weeks ago
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home sleep apnea test, NightOwl™, is now available across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT) designed to offer healthcare providers a simplified, accurate, and efficient way to diagnose obstructive sleep apnea (OSA) from the comfort of an individual's home.
globenewswire.com
- 2 weeks ago
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday, April 23, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
globenewswire.com
- 2 weeks ago
My Top 15 High-Growth Dividend Stocks For April 2025
My Top 15 High-Growth Dividend stocks outperformed SPY and VIG in March, posting a loss of 3.26% compared to SPY's 5.86% and VIG's 4.50%. The April 2025 list offers an average dividend yield of 1.25% and is potentially 31% undervalued, poised for strong long-term returns. Dollar cost averaging into the top 15 stocks each month shows a 68.54% success rate, with 61 out of 89 stocks leading to positive gains.
seekingalpha.com
- 2 weeks ago
New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in The Lancet Respiratory Medicine , demonstrating that CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea (OSA). Analyzing data from over 1 million sleep apnea patients worldwide, the study provides the strongest evidence to date that CPAP therapy not only alleviates OSA symptoms but can also prolong life.
globenewswire.com
- 1 month ago
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
- 1 month ago
NVIDIA's AI Speeds Up MedTech's Digital Boom: 3 Stocks in Focus
RMD, GEHC and MDT are expected to thrive as NVIDIA and other AI leaders' MedTech ventures accelerate digital adoption within the space.
zacks.com
- 1 month ago
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a comprehensive brand evolution designed to unify its brand portfolio to serve more people and healthcare providers worldwide and reflect growing direct to consumer engagement. For 35 years, Resmed has pioneered innovations in respiratory therapy, including CPAP therapy and digital health solutions.
globenewswire.com
- 1 month ago
Is it Worth Adding ResMed Stock to Your Portfolio Now?
Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.
zacks.com
- 1 month ago
5 Best Dividend Growth Stocks to Buy Amid Trade War Fears
Investors searching for safe and consistent income amid global trade war fears. Dividend growth stocks like TSM, TPR, ABM, VRT and RMD are solid choices.
zacks.com
- 1 month ago
ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?
RMD outperforms the industry and the S&P 500 composite due to its success with the cloud-connected AirSense platform.
zacks.com
- 1 month ago
My Top 15 High-Growth Dividend Stocks For March 2025
The SPDR S&P 500 ETF Trust stumbled in February but managed to maintain a positive return in 2025. The Top 15 dividend growth stocks for March 2025 offer an average dividend yield of 1.13% and appear to be about 25% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved a 10.63% compound annual growth rate.
seekingalpha.com
- 1 month ago
8. Profile
Summary
ResMed Inc. RMD
COUNTRY
US
INDUSTRY
Medical - Instruments & Supplies
MARKET CAP
$ 31.3 B
Dividend Yield
0.23%
Description
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Contact
9001 Spectrum Center Boulevard, San Diego, CA, 92123
https://www.resmed.com
IPO
Date
June 2, 1995
Employees
9980
Officers
Mr. Kaushik Ghoshal
Chief Commercial Officer - SaaS
Ms. Vered Keisar
Chief People Officer
Mr. Jim Ellis
Chief Compliance Officer
Mr. Michael J. Farrell BE, MBA, SM
Chief Executive Officer & Chairman
Mr. Brett A. Sandercock
Chief Financial Officer
Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScD
Founder, Chair Emeritus & Director
Mr. Justin Leong
Chief Product Officer
Ms. Yvonne-Katrin Pucknat
Chief Marketing Officer
Mr. Michael J. Rider
Chief Legal Officer & Secretary
Mr. Alastair Robertson
Chief Information Officer